Caligan Partners LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001727492

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 25 positions · Total reported value $1.63B · Top-10 concentration 79.4% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 25.0% · 2 new · 2 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Caligan Partners LP disclosed 25 equity positions with a combined reported value of $1.63B. The filing implies a focused portfolio: its ten largest positions account for 79.4% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were RVMD ($402.68M), LQDA ($245.68M), ABVX ($154.27M). By sector, the heaviest allocations are Health Care 98.2%, Other 1.8%. Versus the prior quarter, allocation shifted toward Other (+0.9pp) and away from Health Care (-0.9pp).

Versus the prior quarter, Caligan Partners LP opened 2 new positions, trimmed 2 and fully exited 3, a turnover rate of 25.0% of positions. The portfolio's overlap with the prior quarter was 82% of names.

The largest new positions opened in Q3 2026 were EPRX ($10.58M), TLGYF ($2.50M).

Of the 3 positions fully exited versus the prior quarter, the largest were XENE ($53.72M), MBX ($11.04M), AGIO ($3.34M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • EPRX EUPRAXIA PHARMACEUTICALS INC · $10.58M
  • TLGYF TCGX ACQUISITION CORP · $2.50M

Fully Exited (vs previous quarter)

  • XENE XENON PHARMACEUTICALS INC · prev qtr: $53.72M
  • MBX MBX BIOSCIENCES INC · prev qtr: $11.04M
  • AGIO AGIOS PHARMACEUTICALS INC · prev qtr: $3.34M

Insider Transactions (Form 4)

Latest Caligan Partners LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-16 Award Liquidia Corp 5,882 — SEC filing
2026-05-19 Buy Liquidia Corp 5,300 $59.98 SEC filing
2026-05-19 Sell Liquidia Corp 5,300 $59.98 SEC filing

All insider transactions →

Fund Profile

Caligan Partners LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 26 US equity positions with a combined value of $1.71B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-113810 (status: Approved), registered 2018-08-10
  • Regulatory AUM (Form ADV): $1.30B as of 2026-05-29
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 3 hedge funds
  • Website: caliganpartners.com

Portfolio Structure

  • 26 positions · $1.71B reported value (Q2 2026)
  • Top 10 holdings = 81.5% of reported value
  • Largest position: LQDA (LIQUIDIA CORPORATION) at 37.8%
  • Average position size: $65.78M

Sector Tilt

  • Health Care 99.1%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 5 new, 8 added, 3 reduced, 5 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 98.2%
Other 1.8%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.96M $402.68M 24.64%
24.64%
Add
2 8.12M $245.68M 15.04%
15.04%
Hold
3 1.56M $154.27M 9.44%
9.44%
Hold
4 2.19M $124.53M 7.62%
7.62%
Hold
5 1.55M $90.73M 5.55%
5.55%
Hold
6 2.50M $62.41M 3.82%
3.82%
Hold
7 5.88M $58.93M 3.61%
3.61%
Add
8 3.08M $57.34M 3.51%
3.51%
Add
9 1.67M $50.65M 3.10%
3.10%
Add
10 3.27M $50.10M 3.07%
3.07%
Add
11 1.51M $49.62M 3.04%
3.04%
Add
12 1.93M $36.73M 2.25%
2.25%
Hold
13 9.19M $33.90M 2.07%
2.07%
Add
14 5.96M $28.85M 1.77%
1.77%
Reduce
15 4.59M $28.83M 1.76%
1.76%
Add
16 1.44M $28.21M 1.73%
1.73%
Hold
17 8.74M $27.70M 1.70%
1.70%
Add
18 2.79M $27.61M 1.69%
1.69%
Add
19 890.21K $26.47M 1.62%
1.62%
Add
20 910.75K $19.92M 1.22%
1.22%
Add
21 1.16M $10.58M 0.65%
0.65%
New
22 1.48M $10.55M 0.65%
0.65%
Reduce
23 923.91K $4.43M 0.27%
0.27%
Hold
24 200.00K $2.50M 0.15%
0.15%
New
25 470.00K $864.80K 0.05%
0.05%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 60% R 60% F1 60% (modelled on 2026-Q1; 6/10 hit)

Low-confidence forecast This fund replaces about 21% of its Top-10 each quarter and backtests at F1 79% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 79% · recall 79% · F1 79% · avg rank error 2.0 · Top-10 turnover 21%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 80% 80% 80% LQDA · ALIM · ANIK · EXEL · LAB · EOLS · AGIO · YMAB · VRNA · ADMA LQDA · ALIM · ANIK · EOLS · EXEL · VRNA · ENTA · AGIO · YMAB · OTLK
2024-Q2 80% 80% 80% LQDA · ALIM · ANIK · EOLS · EXEL · VRNA · AGIO · ENTA · YMAB · OTLK LQDA · ALIM · ANIK · EXEL · BCRX · VRNA · EOLS · AGIO · ENTA · MLYS
2024-Q3 80% 80% 80% LQDA · ALIM · ANIK · EXEL · BCRX · VRNA · EOLS · AGIO · ENTA · MLYS LQDA · VRNA · EXEL · EOLS · ANIK · AGIO · BCRX · YMAB · MLYS · NBP
2024-Q4 90% 90% 90% LQDA · VRNA · EXEL · EOLS · ANIK · AGIO · BCRX · YMAB · MLYS · NBP LQDA · VRNA · EXEL · EOLS · ANIK · BCRX · AGIO · SAGE · YMAB · MLYS
2025-Q1 90% 90% 90% LQDA · VRNA · EXEL · EOLS · ANIK · BCRX · AGIO · SAGE · YMAB · MLYS LQDA · VRNA · EXEL · MLYS · EOLS · SAGE · BCRX · ANIK · AGIO · RVMD
2025-Q2 80% 80% 80% LQDA · VRNA · EXEL · MLYS · EOLS · SAGE · BCRX · ANIK · AGIO · MRUS VRNA · LQDA · EXEL · AGIO · MRUS · EOLS · MLYS · RVMD · ANIK · ABVX
2025-Q3 80% 80% 80% VRNA · LQDA · EXEL · MRUS · AGIO · EOLS · MLYS · RVMD · ANIK · ABVX LQDA · ABVX · MLYS · EXEL · RVMD · AGIO · ADMA · EOLS · MRUS · XENE
2025-Q4 70% 70% 70% LQDA · ABVX · MLYS · EXEL · RVMD · ADMA · AGIO · EOLS · MRUS · XENE LQDA · ABVX · RVMD · MLYS · PCVX · EXEL · ADMA · TNGX · TYRA · XENE
2026-Q1 80% 80% 80% LQDA · ABVX · RVMD · MLYS · PCVX · EXEL · ADMA · TNGX · TYRA · XENE LQDA · ABVX · PCVX · XENE · MLYS · EXEL · CGON · TNGX · TYRA · SYRE
2026-Q2 ★ 60% 60% 60% LQDA · ABVX · PCVX · XENE · MLYS · EXEL · CGON · TYRA · TNGX · SYRE LQDA · ABVX · PCVX · EXEL · TNGX · AVTX · XENE · RVMD · LBRX · IMCR

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings5 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return+12.74%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+29.75%vs benchmark
Barra annualised vol55.5%Model estimate
Realised vol47.4%Annualised in window
Weighted beta0.98Raw exposure
Factor / specific risk42% / 58%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)77.288.299.3110.4121.510-0110-2311-16Caligan Partners LPQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)+12.74%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+29.75%Portfolio − benchmark
Arithmetic return sum+13.45%Difference vs compounded is the cross term
Weighted raw beta0.98Weighted holding betas
Realised volatility (annualised)47.43%Daily returns in window
Barra model volatility (annualised)55.46%Factor + specific
Factor share of variance42.1%Barra factors
Specific share of variance57.9%Stock residuals
Reported value$829.1M13F long US equity

2. Return attribution

The +13.45% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +2.39% 17.8%
Momentum & Growth 3 -13.73% -102.1%
Volatility & Tail Risk 7 +1.12% 8.3%
Industry 12 +6.98% 51.9%
Specific 1 +16.69% 124.1%
Return attribution (style + industry, %)-15.3-7.6+0.0+7.6+15.3Amihud Illiquidity-0.65Turnover+0.87Short-term Reversal+0.89Non-linear Size+1.62Growth-1.72Mid Cap-1.85Leverage (Downside Vol)-1.92Size+2.26Skewness+3.98Residual Volatility+6.29Kurtosis+6.40Health Care+6.98Momentum-12.90Historical Volatility-14.14
Factor Type Exposure Factor return Contribution Share of |return|
Specific Specific — — +16.69% 124.1%
Health Care Industry +1.00 +6.98% +6.98% 51.9%
Kurtosis Style +0.85 +7.51% +6.40% 47.6%
Residual Volatility Style +1.91 +3.29% +6.29% 46.8%
Skewness Style -0.91 -4.39% +3.98% 29.6%
Size Style -1.16 -1.95% +2.26% 16.8%
Non-linear Size Style +1.60 +1.01% +1.62% 12.0%
Short-term Reversal Style +1.02 +0.87% +0.89% 6.6%
Turnover Style -0.18 -4.80% +0.87% 6.5%
Beta Style +0.12 +4.44% +0.51% 3.8%
Liquidity Style +0.39 +0.36% +0.14% 1.0%
Amihud Illiquidity Style +1.45 -0.45% -0.65% -4.8%
Growth Style -0.99 +1.75% -1.72% -12.8%
Mid Cap Style +0.96 -1.94% -1.85% -13.8%
Leverage (Downside Vol) Style +1.12 -1.71% -1.92% -14.2%
Momentum Style +3.22 -4.00% -12.90% -95.9%
Historical Volatility Style +1.01 -14.00% -14.14% -105.1%

3. Risk attribution

Annualised volatility is 55.46%; factor risk explains 42.1% of variance and specific risk 57.9%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-62.6-31.3+0.0+31.3+62.6Growth-2.13Kurtosis+0.39Beta+0.41Skewness+0.43Leverage (Downside Vol)+0.51Amihud Illiquidity+0.69Mid Cap+1.40Short-term Reversal+1.61Historical Volatility+2.29Size+2.71Residual Volatility+3.45Health Care+9.00Momentum+21.23Specific+57.93
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 57.9% +32.13% 32.1%
Momentum Style +3.22 21.2% +11.78% 11.8%
Health Care Industry +1.00 9.0% +4.99% 5.0%
Residual Volatility Style +1.91 3.5% +1.91% 1.9%
Size Style -1.16 2.7% +1.50% 1.5%
Historical Volatility Style +1.01 2.3% +1.27% 1.3%
Short-term Reversal Style +1.02 1.6% +0.89% 0.9%
Mid Cap Style +0.96 1.4% +0.78% 0.8%
Amihud Illiquidity Style +1.45 0.7% +0.38% 0.4%
Leverage (Downside Vol) Style +1.12 0.5% +0.28% 0.3%
Skewness Style -0.91 0.4% +0.24% 0.2%
Beta Style +0.12 0.4% +0.22% 0.2%
Kurtosis Style +0.85 0.4% +0.22% 0.2%
Growth Style -0.99 -2.1% -1.18% -1.2%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-1.6-0.31.02.33.7Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.16 +2.10 -3.26
Non-linear Size +1.60 +1.68 -0.07
Mid Cap +0.96 +0.13 +0.83
Beta +0.12 +1.29 -1.18
Momentum +3.23 +0.72 +2.51
Short-term Reversal +1.02 -0.64 +1.66
Residual Volatility +1.91 -0.40 +2.31
Historical Volatility +1.01 +0.86 +0.15
Liquidity +0.39 +0.11 +0.28
Amihud Illiquidity +1.45 +1.16 +0.29
Turnover -0.18 +0.21 -0.39
Growth -0.99 +0.58 -1.57
Leverage (Downside Vol) +1.12 +0.14 +0.97
Skewness -0.91 +0.24 -1.14
Kurtosis +0.85 +0.21 +0.64
Max Drawdown +0.01 -0.08 +0.09

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Health Care 100.0% 1.7% +17.96% +8.29% +24.98% +0.17% +9.51% +17.82%
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Total +23.98% +16.01% -6.33% +33.66%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
RVMD REVOLUTION MEDICINES INC Health Care 48.57% -18.70% -9.08% Add
LQDA LIQUIDIA CORPORATION Health Care 29.63% +86.29% +25.57% Hold
EXEL EXELIXIS INC Health Care 10.94% +14.88% +1.63% Hold
TNGX TANGO THERAPEUTICS INC Health Care 7.53% -3.13% -0.24% Hold
SGMT SAGIMET BIOSCIENCES INC Health Care 3.33% +2.53% +0.08% Add
Contribution rank Symbol Sector Weight Return Contribution
1 LQDA Health Care 29.63% +86.29% +25.57%
2 EXEL Health Care 10.94% +14.88% +1.63%
3 SGMT Health Care 3.33% +2.53% +0.08%
4 TNGX Health Care 7.53% -3.13% -0.24%
5 RVMD Health Care 48.57% -18.70% -9.08%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned +12.74%, versus -17.01% for the QQQ synthetic benchmark — an excess of +29.75%.
  2. Return attribution: the largest positive style/industry contributions came from Health Care +6.98%, Kurtosis +6.40%, Residual Volatility +6.29%; the largest drags came from Historical Volatility -14.14%, Momentum -12.90%, Leverage (Downside Vol) -1.92%. Specific (stock-level) return contributed +16.69%.
  3. Risk attribution: Barra model volatility is 55.46% annualised; factor risk explains 42% of variance and specific risk 58%. The largest factor risk sources are Momentum 21.2%, Health Care 9.0%, Residual Volatility 3.5%.
  4. Style tilt: size -1.16, momentum +3.23, volatility +1.01, liquidity +0.39; the weighted raw beta is 0.98. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +16.01% and interaction -6.33%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Caligan Partners LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Caligan Partners LP reported 25 equity positions worth $1.63B in aggregate; its largest disclosed positions were RVMD ($402.68M), LQDA ($245.68M), ABVX ($154.27M).

How large is Caligan Partners LP's portfolio?

Caligan Partners LP reported $1.63B of long equity holdings across 25 positions as of 2026-Q3. Top-10 holdings account for 79.4% of reported value.

What is Caligan Partners LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/caligan-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →